These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 22246397)

  • 21. Meta-analysis of the predictive value of KRAS mutations in treatment response using cetuximab in colorectal cancer.
    Tsoukalas N; Tzovaras AA; Tolia M; Kostakis ID; Papakostidi A; Pistamaltzian N; Ardavanis A
    J BUON; 2012; 17(1):73-8. PubMed ID: 22517696
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer.
    Malapelle U; Sgariglia R; De Stefano A; Bellevicine C; Vigliar E; de Biase D; Sepe R; Pallante P; Carlomagno C; Tallini G; Troncone G
    J Clin Pathol; 2015 Apr; 68(4):265-9. PubMed ID: 25609577
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].
    Fabian P; Berkovcová J
    Cesk Patol; 2011 Oct; 47(4):154-8. PubMed ID: 22145213
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cetuximab-mediated ADCC activity is correlated with the cell surface expression level of EGFR but not with the KRAS/BRAF mutational status in colorectal cancer.
    Seo Y; Ishii Y; Ochiai H; Fukuda K; Akimoto S; Hayashida T; Okabayashi K; Tsuruta M; Hasegawa H; Kitagawa Y
    Oncol Rep; 2014 May; 31(5):2115-22. PubMed ID: 24626880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer.
    Van Cutsem E; Lenz HJ; Köhne CH; Heinemann V; Tejpar S; Melezínek I; Beier F; Stroh C; Rougier P; van Krieken JH; Ciardiello F
    J Clin Oncol; 2015 Mar; 33(7):692-700. PubMed ID: 25605843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expression of growth factor receptors and targeting of EGFR in cholangiocarcinoma cell lines.
    Xu L; Hausmann M; Dietmaier W; Kellermeier S; Pesch T; Stieber-Gunckel M; Lippert E; Klebl F; Rogler G
    BMC Cancer; 2010 Jun; 10():302. PubMed ID: 20565817
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo.
    Hsu YF; Ajona D; Corrales L; Lopez-Picazo JM; Gurpide A; Montuenga LM; Pio R
    Mol Cancer; 2010 Jun; 9():139. PubMed ID: 20529262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cetuximab in metastatic colorectal cancer.
    Broadbridge VT; Karapetis CS; Price TJ
    Expert Rev Anticancer Ther; 2012 May; 12(5):555-65. PubMed ID: 22594891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand-dependent activation of EGFR in follicular dendritic cells sarcoma is sustained by local production of cognate ligands.
    Vermi W; Giurisato E; Lonardi S; Balzarini P; Rossi E; Medicina D; Bosisio D; Sozzani S; Pellegrini W; Doglioni C; Marchetti A; Rossi G; Pileri S; Facchetti F
    Clin Cancer Res; 2013 Sep; 19(18):5027-38. PubMed ID: 23888072
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
    Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
    Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
    [TBL] [Abstract][Full Text] [Related]  

  • 32. To give or not to give anti-epidermal growth factor receptor (EGFR) monoclonal antibodies to patients with KRAS G13D mutation in advanced colorectal cancer.
    Kim R; Kubal T
    Clin Colorectal Cancer; 2012 Jun; 11(2):85-7. PubMed ID: 22169039
    [No Abstract]   [Full Text] [Related]  

  • 33. Mitogen-activated protein kinase phosphatase-1 (MKP-1) impairs the response to anti-epidermal growth factor receptor (EGFR) antibody cetuximab in metastatic colorectal cancer patients.
    Montagut C; Iglesias M; Arumi M; Bellosillo B; Gallen M; Martinez-Fernandez A; Martinez-Aviles L; Cañadas I; Dalmases A; Moragon E; Lema L; Serrano S; Rovira A; Rojo F; Bellmunt J; Albanell J
    Br J Cancer; 2010 Mar; 102(7):1137-44. PubMed ID: 20234366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
    Van Cutsem E; Köhne CH; Láng I; Folprecht G; Nowacki MP; Cascinu S; Shchepotin I; Maurel J; Cunningham D; Tejpar S; Schlichting M; Zubel A; Celik I; Rougier P; Ciardiello F
    J Clin Oncol; 2011 May; 29(15):2011-9. PubMed ID: 21502544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cetuximab-based treatment of metastatic anal cancer: correlation of response with KRAS mutational status.
    Lukan N; Ströbel P; Willer A; Kripp M; Dinter D; Mai S; Hochhaus A; Hofheinz RD
    Oncology; 2009; 77(5):293-9. PubMed ID: 19923868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Mutation of EGFR signaling pathway and therapy for metastatic colorectal cancer].
    Nozawa K; Watanabe T
    Gan To Kagaku Ryoho; 2010 May; 37(5):791-4. PubMed ID: 20495308
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
    Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
    Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [EGFR-blockade by antibody Cetuximab inhibits the growth of human gastric cancer xenograft in nude mice and its possible mechanism].
    Zhang J; Ji J; Yuan F; Ma T; Ye ZB; Yu YY; Liu BY; Zhu ZG
    Zhonghua Zhong Liu Za Zhi; 2009 Feb; 31(2):85-9. PubMed ID: 19538880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK1/2 inhibitors AS703026 and AZD6244 may be potential therapies for KRAS mutated colorectal cancer that is resistant to EGFR monoclonal antibody therapy.
    Yoon J; Koo KH; Choi KY
    Cancer Res; 2011 Jan; 71(2):445-53. PubMed ID: 21118963
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined cetuximab and genistein treatment shows additive anti-cancer effect on oral squamous cell carcinoma.
    Park SJ; Kim MJ; Kim YK; Kim SM; Park JY; Myoung H
    Cancer Lett; 2010 Jun; 292(1):54-63. PubMed ID: 19959278
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.